



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

14 April 2020 (#21)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • **Stellenbosch Campus** lizelk@sun.ac.za

Important Notice

[NOT-OD-20-096](#) NIH Plans to Migrate eRA Modules and Data to the Cloud April 17-20; All Systems Unavailable During Migration Window. The electronic Research Administration (eRA) is planning to migrate its modules and data to the cloud April 17-20, 2020 (Fri-Mon). As a result, during this cloud migration, from 8 a.m. ET on Friday, April 17 to 8 p.m. ET on Monday, April 20, all eRA modules (eRA Commons, ASSIST, IAR, iEdison, etc.) and the era.nih.gov website will be unavailable. The eRA Service Desk's ticketing system will be offline and agents will be able to offer only limited support during the migration window. The eRA Service Desk will be fully operational on Tuesday, April 21.

[NOT-AA-20-005](#) Notice of Intent to Publish a Funding Opportunity Announcement for Alcohol-HIV/AIDS Program Project Comorbidities, Coinfections, and Complications Research: Intervention and Cross-Cutting Foundational Research (P01 Clinical Trial Optional). The National Institute on Alcohol Abuse and Alcoholism (NIAAA) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications for research on human studies that will advance operations or implementation research in the context of alcohol and HIV/AIDS by facilitating the development of: (1) broader systems approaches for monitoring complex HIV and alcohol-related morbidity and mortality, and (2) interventions to reduce the impact of alcohol on HIV disease progression and transmission. Estimated Publication Date of Funding Opportunity Announcement: May 01, 2020 First Estimated Application Due Date: November 17, 2020. Estimated Total Funding: \$10 million in fiscal year 2021. Expected Number of Awards: 8. Estimated Award Ceiling: Up to \$1 million in direct costs per year.

[NOT-AI-20-041](#): Pre-Solicitation Notice: Preclinical and Translational Vaccine Development for HIV and Other Candidate Agents, RFP: 75N93019R00023. The development of a safe and efficacious preventive HIV-1 vaccine is one of the highest priorities of the National Institute of Allergy and Infectious Diseases (NIAID). NIAID supports a portfolio of preclinical, translational, and clinical research to advance HIV vaccine efforts. The Division of AIDS (DAIDS) supports research programs to discover novel vaccine strategies, assess correlates of immunogenicity and of protections elicited by experimental vaccines and provides an infrastructure for the manufacturing and testing of novel products. To achieve this goal, the Government anticipates awarding Indefinite Delivery/Indefinite Quantity (IDIQ) contracts to multiple Contractors that meet the overall qualifications for individual Task Areas. The purpose of this solicitation is to award multiple IDIQ contracts to support the full range of activities for preclinical and translational support services from initial product discovery through full (CGMP) manufacturing and readiness for clinical trials and/or product licensure. NIAID anticipates that multiple Indefinite Delivery/Indefinite Quantity (IDIQ) contract awards for the Base contracts will be on or about June 9, 2021. The ordering period for these contracts will be from June 9, 2021 through June 8, 2028. Contractors will not be required to make any deliveries under the contracts after June 8, 2031. Offerors may respond to one Task Area only, to several Task Areas, or to all Task Areas. Task Area G, Scientific, Quality and Regulatory Support Services, is set aside for small business concerns only. Any responsible offeror may submit a proposal which will be considered by the Agency. This RFP will be available electronically on/about April 10, 2020 and may be accessed through beta.SAM.gov. Contracting Officer: patrick.finn@nih.gov

[NOT-AI-20-042](#): Pre-Solicitation Notice: Immunology Quality Assessment (IQA) Program, RFP: 75N93020R00007. The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology, leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID, Division of AIDS (DAIDS), has a requirement for reliable laboratory data, important for the meaningful interpretation of therapeutic and prevention clinical trials/studies and for the appropriate management of

subjects enrolled in these studies. Immunological tests, as well as frozen peripheral mono-nuclear cells (PBMCs) for future or off-site testing, are included in many DAIDS-supported trials. It is, therefore, important to evaluate objectively the ability of laboratories to process PBMC and perform tests reliably, and to enhance laboratory performance by providing assistance and training when deficiencies are identified. The current Immunology Quality Assessment (IQA) Program (under Contract No. HHSN272201400014C) is held by Duke University. The purpose of the proposed contract will be to continue to provide a Immunology Quality Assessment Program (IQA) resource to evaluate and enhance the ability of U.S. and non-U.S. laboratories (Labs) to participate in NIAID-funded and collaborative clinical studies by: (1) monitoring the ability of Labs to reliably perform study-specified immunological tests and cryopreserve peripheral blood mononuclear cells (PBMCs) and other human biological samples; (2) facilitating the optimization, standardization and validation of immunological assay methodologies, with focus on laboratory-developed-tests (LDTs) for implementation in NIAID-supported studies; (3) helping Labs meet sponsor and regulatory requirements for good clinical laboratory practices (GCLP) and submission of data to regulatory agencies; and (4) hosting and maintaining an electronic data management system and document library in support of contract activities. Increases in the level of effort, in order to support unanticipated increases in demand related to support of additional Labs, as well as performance of late-stage assay validation and/or immunological assay testing of clinical samples in a CLIA-certified laboratory, are also within the scope of the contract and would be implemented through the exercise of contract options, at the discretion of the Government. Any responsible offeror may submit a proposal, which will be considered by the Agency. This RFP will be available electronically, on/about April 16, 2020, and may be accessed through SAM <http://beta.sam.gov/> Contracting Officer: christopher.weaver@nih.gov

NOT-CA-20-044: Notice of Special Interest (NOSI): Single-Cell Proteomics for Interrogating Premalignant and Early Malignant Lesions. The purpose of this Notice of Special Interest (NOSI) is to: (1) encourage investigators to apply single-cell proteomics for interrogation of premalignant and early malignant lesions; (2) develop new multiparametric biomarkers for cancer screening, early detection and risk assessment; and, (3) establish a biomarkers workflow for a wide coverage of disease variability and individuals at the population level. This notice applies to due dates on or after May 25, 2020 and subsequent receipt dates through May 8, 2023.

NOT-CA-20-045: Notice of Special Interest (NOSI): Advancing Cancer Data Repositories and Knowledgebases. The purpose of this Notice is to inform potential applicants of the special interest of the National Cancer Institute (NCI) in encouraging the submission of applications to either [PAR-20-089](#) Biomedical Data Repository (U24-Clinical Trial Not Allowed) or [PAR-20-097](#) Biomedical Knowledgebase (U24-Clinical Trial Not Allowed) FOAs, focused on the establishment of new, or continued development of established cancer data resources that use state-of-the-art and cost-effective technologies and approaches, and that are of high value to the broad cancer research community. This NOSI applies to applications for both data repositories and knowledgebases.

NOT-EB-20-007: Notice of Special Interest (NOSI): Development of Biomedical Technologies for Coronavirus Disease 2019 (COVID-19) The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for accelerating the development, translation, and commercialization of technologies to address Coronavirus Disease 2019 (COVID-19). The NIBIB is seeking applications to develop life-saving technologies that can be ready for commercialization within one to two years. Please direct all inquiries to COVID19NIBIB@nih.gov Example technologies include, but are not limited to:

- Rapid point-of-care and home-based testing/diagnostics
- Wearable, implantable, and remote sensors/imagers for physiological monitoring
- Medical imaging technologies and algorithms/artificial intelligence (AI) for rapid detection, diagnosis, and monitoring of lung infection
- Non-contact sensing and imaging for rapid mass screening and vital sign assessment
- Digital health platforms and models that integrate data, assess risk, and provide illness surveillance and management tools
- Technologies (including simulation platforms) for training healthcare workers and optimizing clinical workflows
- Robotic and automation technologies to limit caregivers' exposure and/or reduce burden on the healthcare system
- Technologies for protecting healthcare workers, first responders, and caregivers
- Oxygenation systems (e.g. ECMO, ventilators, intubation) and components designed for rapid deployment, access, and potential operation by minimally trained personnel
- High-confidence disinfection technologies
- Novel therapeutic strategies using engineered biological systems, including cell-based and synthetic biology technologies.

NOT-ES-20-015: Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19). NIEHS is issuing this Notice of Special Interest (NOSI) to address the urgent need for mission-relevant research to understand the impact of environmental exposures on Coronavirus Disease 2019 (COVID-19) and its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2). NIEHS is particularly interested in applications that will provide insight into the role of environmental exposures in pathogenicity, transmission, individual susceptibility, or prevention and intervention strategies. **First Available Due Date:** May 01, 2020. **Expiration Date:** May 04, 2021

1. Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD) Exploratory/Developmental Research Projects (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AA-20-008](#)

Type: UH2

Application Due Date: May 19, 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The National Institute on Alcohol Abuse and Alcoholism (NIAAA) solicits research applications to address significant challenges in Fetal Alcohol Spectrum Disorders (FASD) research in the areas of diagnosis/screening, etiology, interventions and treatment. Cooperative Agreement (UH2) applications in response to this FOA should propose exploratory/developmental projects, based on new and innovative concepts, approaches, and technologies. This solicitation is open to all eligible institutions. To maximize the impact of their research, awardees will be encouraged to establish a collaborative relationship with the NIAAA-supported Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD) consortium. For this FOA no preliminary data are required, expected, or encouraged. However, if available, minimal preliminary data are allowed. Preliminary data are defined as material which the applicant has independently produced and not yet published in a peer-reviewed journal. All preliminary data must be clearly marked and limited to one-half page, which may include one figure. *Applications including data more than one-half page or more than one figure will be considered noncompliant with the FOA instructions and will not go forward to review.*

Budget: NIAAA intends to commit \$750,000 in FY 2021 to fund 1 to 3 awards. Application budgets must not exceed \$175,000 direct cost in the first year and \$100,000 direct cost in the second year. The scope of the proposed project should determine the project period. The maximum period is 2 years.

2. Limited Competition: International Epidemiology Databases to Evaluate AIDS (leDEA) (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AI-20-023](#)

Type: U01

Application Due Date: August 4, 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) solicits applications to continue the International epidemiology Databases to Evaluate AIDS (leDEA) Program. The leDEA program is comprised of 7 regional data center awards, which bring together clinical and research data within regions, and in collaboration monitor and guide the response to the HIV/AIDS epidemic. This research includes work on the long-term impact of HIV and its treatment, the epidemiology of common co-infections (e.g., hepatitis and tuberculosis). Research also evaluates health care utilization including medications, procedures, and vaccines, studies of co-morbidities such as cancer, disruption of physiological and metabolic processes leading to end organ impairment, mental health and alcohol and substance use. Data sources include clinical care, surveillance or research protocols as well as a Sentinel Research Network which collects data in a more intensive prospective cohort to understand the impact of non-communicable disease in HIV and allow for inferences across the network. This funding announcement also asks leDEA to include a cohort of persons with tuberculosis (TB) to evaluate TB treatment outcomes. leDEA facilitates access to data working with data consumers at the clinic, national, and global level and creating data tools.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. Applicants may request a project period of up to 5 years.

3. Utilizing Cohort Studies to Address Health Outcomes in Cancer Survivors (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-CA-20-030](#)

Type: UG3/UH3

Application Due Date: July 7, 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications to support research in new and innovative cohort studies that identify clinical, lifestyle, genomic, and other factors that affect health outcomes (e.g., morbidity, mortality, quality of life, physical, social, and psychological outcomes) in cancer survivors (i.e., from diagnosis to the end of life). This FOA intends to support research that requires the creation of a new prospective cohort study that addresses a gap in knowledge pertaining to the health of cancer survivors. Applications must identify the scientific gap that the study addresses, which may include emerging treatments, less common cancer sites, and/or understudied populations of cancer survivors with disparities.

Sample size and proposed data collection must be driven by the scientific questions proposed and should include information from all the following five domains in order to cover the full extent of the cancer survivor experience: 1) disease characteristics (e.g., type, stage, tumor biomarkers), 2) individual survivor characteristics (e.g., comorbidities, socioeconomic status [SES], social connections, information seeking, access to care measures), 3) treatment, treatment-related effects, and follow-up care (e.g. dose, adverse events, palliative care), 4) behavioral and lifestyle factors (e.g., diet, physical activity, adherence) and 5) quality of life outcomes (health-related quality of life (HRQOL), patient symptom reports). These domains may represent exposures and/or outcomes, depending on the research questions, and should be measured at multiple timepoints, when appropriate. The UG3/UH3 mechanism has two phases: the UG3 Planning-Exploratory Phase focused on the recruitment of study participants and data collection/utilization, and the UH3 Implementation Phase focused on completing the research agenda. Milestones to be accomplished in the UG3 phase for transition to the UH3 phase should be proposed by the Principal Investigator(s) (PIs), which will require NCI review and approval before the grant is awarded, and must include a timeline for recruitment and show feasibility for data collection and analysis. Recruitment is not required to be completed in the UG3 phase, but reasonable progress should be demonstrated to ensure that all aims will be completed in the UH3 phase.

Budget: NCI intends to commit \$3.9 million in FY 2021 to fund up to 3 awards. Application budgets are limited to \$750,000 direct costs per year in years 1 and 2. Budgets in years 3-6 are not limited but must reflect the actual needs of the proposed project. The proposed project period for the initial development phase (UG3) must not exceed 2 years and the total duration of the UG3/UH3 phases combined may not exceed 6 years.

4. CBER FY20 FOA for AAV vector manufacturing for diseases affecting very small populations (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-FD-20-032](#)

Type: R01

Application Due Date: June 23, 2020 by 11:59 PM Eastern Time.

Funding Opportunity Announcement: CBER seeks to advance the development of gene therapies for diseases affecting very small populations, potentially even single individuals, by enhancing innovations in the manufacture of Adeno-associated virus (AAV) vectors

Budget: Award(s) will provide one (1) year of support and include future recommended support for two (2) additional years contingent upon annual appropriations, availability of funding and satisfactory awardee performance. FDA/CBER intends to fund up to \$800,000 for fiscal year 2020 in support of this grant program. It is anticipated that up to two awards will be made, not to exceed \$400,000 in total costs (direct plus indirect), per award. The scope of the proposed project should determine the project period. The maximum project period is three (3) years.

**Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University**
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University
2038 Wilcocks Building, Ryneveld Street
Enquiries: *Lizel*
e: lizelk@sun.ac.za | t: +27 21 808 2105